植入纳曲酮、口服美沙酮或舌下丁丙诺啡治疗阿片依赖女性的产科结局回顾性队列研究
本研究回顾性分析2001至2010年间接受植入纳曲酮、口服美沙酮或舌下丁丙诺啡治疗的阿片依赖女性及年龄匹配对照, linkage 产科记录。纳曲酮组分娩率显著高于其他三组,妊娠丢失率高于丁丙诺啡组和对照组,但与美沙酮组无统计学差异;妊娠并发症率高于对照组,但与美沙酮或丁丙诺啡组无显著差异。
要点
- 植入纳曲酮组分娩率显著高于美沙酮、丁丙诺啡及对照组。
- 纳曲酮组妊娠丢失率显著高于丁丙诺啡组和对照组,与美沙酮组无差异。
- 纳曲酮组妊娠并发症率高于对照组,但与美沙酮或丁丙诺啡组无显著差异。
核心结论
- 植入纳曲酮治疗的阿片依赖女性分娩率高于美沙酮或丁丙诺啡治疗女性及年龄匹配对照。
- 纳曲酮组妊娠并发症率高于对照组,但与美沙酮或丁丙诺啡组总体无显著差异。
研究设计与样本
- 回顾性队列研究,纳入2001至2010年间接受植入纳曲酮、口服美沙酮或舌下丁丙诺啡治疗的阿片依赖女性及年龄匹配对照。
- 通过链接助产士、医院、急诊和死亡登记记录识别妊娠及健康事件。
主要发现
- 纳曲酮组妊娠丢失率显著高于丁丙诺啡组(p=0.018)和对照组(p<0.001),与美沙酮组无统计学差异(p=0.210)。
- 纳曲酮组分娩率显著高于所有三个比较组(p<0.001)。
- 纳曲酮组妊娠期医院和急诊就诊率与美沙酮或丁丙诺啡组无统计学差异,妊娠和分娩总体并发症亦无差异。
- 纳曲酮组妊娠期总体并发症率显著高于对照组。
临床怎么用
- 对于阿片依赖孕妇,植入纳曲酮可作为美沙酮或丁丙诺啡之外的一种选择,但需关注妊娠丢失和并发症风险。
- 临床决策时应结合患者具体情况,权衡纳曲酮植入的获益与潜在产科风险。
局限性
- 回顾性队列设计可能存在混杂偏倚。
- 妊娠丢失仅纳入需要医院或急诊就诊的事件,可能低估实际发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid pharmacotherapies play an important role in the treatment of opioid-dependent women; however, very little is known about the safety of naltrexone in pregnant patients. OBJECTIVE: This study examined the obstetric health of opioid-dependent women who were treated with implant naltrexone during pregnancy, and compared them with women treated with methadone and/or buprenorphine and a cohort of non-opioid-dependent controls. METHODS: Women treated with implant naltrexone, oral methadone or sublingual buprenorphine between 2001 and 2010, along with a cohort of age-matched controls, were linked with records from midwives, hospital and emergency departments (EDs) and the death registry to identify pregnancy and health events that occurred during pregnancy and in the post-partum period. RESULTS: Overall rates of pregnancy loss (requiring hospital or ED attendance) were significantly elevated in naltrexone-treated women compared with buprenorphine-treated women (p = 0.018) and controls (p < 0.001); however, they were not statistically different to methadone-treated women (p = 0.210). Birth rates in women on naltrexone implant treatment were significantly higher than in all three comparison groups (p < 0.001). Rates of hospital and ED attendance during pregnancy in the naltrexone-treated women were not statistically different to those of either the methadone or buprenorphine groups, and neither were overall complications during pregnancy and labour. Overall rates of complications during pregnancy were significantly higher in the naltrexone-treated women than in the controls. CONCLUSION: Opioid-dependent women treated with naltrexone implant had higher rates of birth than the other three groups (methadone- or buprenorphine-treated women, or age-matched controls). Overall rates of complications during pregnancy were elevated in naltrexone-treated women when compared with the control group, but were generally not significantly different to rates in methadone- or buprenorphine-treated women.
引用
- Kelty E, Hulse G. A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls. Drugs. 2017. PMID: 28536980. doi:10.1007/s40265-017-0762-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。